Lymphoplasmacytic lymphoma laboratory findings: Difference between revisions

Jump to navigation Jump to search
Line 49: Line 49:
*[[Cold agglutinins]] are [[antibodies]] that attack and kill [[red blood cells]], especially at cooler temperatures. These dead cells can then build up and block [[blood vessels]]. A blood test can be used to detect these [[antibodies]].
*[[Cold agglutinins]] are [[antibodies]] that attack and kill [[red blood cells]], especially at cooler temperatures. These dead cells can then build up and block [[blood vessels]]. A blood test can be used to detect these [[antibodies]].
===Beta-2 microglobulin (β2M)===
===Beta-2 microglobulin (β2M)===
*This test measures another [[protein]] made by the [[cancer cells]] in LPL. This [[protein]] itself doesn’t cause any problems, but it’s a useful indicator of a patient’s [[prognosis]] (outlook). High levels of β2M are linked with a worse outlook.
*This test measures another [[protein]] made by the [[cancer cells]] in LPL.  
*This [[protein]] itself doesn’t cause any problems, but it’s a useful indicator of a patient’s [[prognosis]] (outlook).
*High levels of β2M are linked with a worse outlook.
 
===Urinanalysis===
===Urinanalysis===
*[[Proteinuria]]
*[[Proteinuria]]

Revision as of 02:30, 21 February 2019

Lymphoplasmacytic lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lymphoplasmacytic Lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lymphoplasmacytic lymphoma laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lymphoplasmacytic lymphoma laboratory findings

CDC on Lymphoplasmacytic lymphoma laboratory findings

Lymphoplasmacytic lymphoma laboratory findings in the news

Blogs on Lymphoplasmacytic lymphoma laboratory findings

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Lymphoplasmacytic lymphoma laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]

Overview

Patients with lymphoplasmacytic lymphoma usually appear oriented to time, place, and person. Physical examination of patients with lymphoplasmacytic lymphoma is usually remarkable for various findings depending on the degree of tissue infiltration by malignant tumor cells, hyperviscosity syndrome, and accumulation of paraprotein.

Laboratory Findings

Complete blood count

Peripheral smear

===Chemistry Lab tests===[2]

Platelet function test and blood coagulation studies

Mutational analysis

Cryocrit

Cold agglutinins

Beta-2 microglobulin (β2M)

  • This test measures another protein made by the cancer cells in LPL.
  • This protein itself doesn’t cause any problems, but it’s a useful indicator of a patient’s prognosis (outlook).
  • High levels of β2M are linked with a worse outlook.

Urinanalysis

Serology

Antibody titers in patients with peripheral neuropathy

References

  1. García-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A; et al. (2001). "Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases". Br J Haematol. 115 (3): 575–82. PMID 11736938.
  2. Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA; et al. (2009). "Screening panels for detection of monoclonal gammopathies". Clin Chem. 55 (8): 1517–22. doi:10.1373/clinchem.2009.126664. PMC 3773468. PMID 19520758.
  3. Penny R, Castaldi PA, Whitsed HM (1971). "Inflammation and haemostasis in paraproteinaemias". Br J Haematol. 20 (1): 35–44. PMID 4924493.
  4. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X; et al. (2013). "MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction". Blood. 121 (11): 2051–8. doi:10.1182/blood-2012-09-454355. PMC 3596964. PMID 23321251.

Template:WH Template:WS